

National Instrument 51-102

NOTICE OF CHANGE IN CORPORATE STRUCTURE

Pursuant to Section 4.9 of National Instrument 51-102 – *Continuous Disclosure Obligations*, Blox Labs Inc. hereby confirms as follows:

1. **The names of the parties to the transaction.**

Blox Labs Inc. ("**Blox**" or the "**Company**")
Best Cannabis Products Inc. ("**BCP**")

2. **A description of the transaction.**

On February 28, 2019, Blox and BCP entered into a definitive share exchange agreement (the "**Agreement**") wherein Blox would acquire all of the outstanding common shares of BCP in exchange for common shares of Blox (the "**Transaction**").

The Company completed a non-brokered private placement on August 29, 2019 wherein it issued 47,923,330 common shares ("**Shares**") at a price of \$0.05 per Share for gross proceeds of \$2,396,167. No finder's fees were paid in connection with this financing. All of the securities issued under the private placement are subject to a four month hold period.

After completing the private placement, the Company then completed the acquisition of all of the issued and outstanding BCP Shares by issuing one Share for each issued and outstanding BCP Share, all in accordance with the terms of the Agreement. As a result, an aggregate of 234,800,000 Shares were issued to the holders of the BCP Shares

Blox completed a name change to Sire Bioscience Inc. ("**Sire**" or the "**Resulting Issuer**").

After giving effect to the Transaction, the Resulting Issuer has 400,222,327 Shares issued and outstanding, 22,572,000 Resulting Issuer Shares are reserved for issuance upon the exercise of Resulting Issuer warrants and 10,880,000 Resulting Issuer Shares are reserved for issuance upon the exercise of Resulting Issuer stock options.

The Company is a reporting issuer in the Provinces of British Columbia, Alberta and Ontario and the Resulting Issuer Shares are listed and posted for trading on the Canadian Securities Exchange under the trading symbol "SIRE".

3. **The effective date of the transaction.**

September 11, 2019

4. **The names of each party, if any, that ceased to be a reporting issuer subsequent to the transaction and of each continuing entity.**

The name of the reporting issuer is now Sire Bioscience Inc.

5. **The date of the reporting issuer's first financial year-end subsequent to the transaction.**

From an accounting perspective, the Company's first financial year-end subsequent to the transaction will be September 30, 2019.

6. **The periods, including the comparative periods, if any, of the interim and annual financial statements required to be filed for the reporting issuer's first financial year subsequent to the transaction.**

BCP is required to file financial statements for the period ended September 30, 2018, for the three month period ended December 31, 2018, and for the six month period ended March 31, 2019 (which financial statements pre-date the completion of the Transaction).

Sire has decided to change its financial year end from March 31 to September 30 to be in alignment with the financial year end of BCP. Assuming that Sire maintains its year end to September 30, the following is a summary of the Company's financial reporting periods in its first financial year subsequent to the completion of the Transaction:

- (a) 12 months ended September 30, 2019 (audited) compared to the period ended September 30, 2018 (audited), due by January 28, 2020;
- (b) 3 months ended December 31, 2019 compared to the 3 month period ended December 31, 2018, due by March 2, 2020;
- (c) 6 months ended March 31, 2020 compared to the 6 month period ended March 31, 2019, due by June 1, 2020;
- (d) 9 months ended June 30, 2020 compared to the 9 month period ended June 30, 2019, due by August 31, 2020; and
- (e) 12 months ended September 30, 2020 (audited) compared to the 12 months ended September 30, 2019 (audited), due by January 28, 2021.

7. **Documents filed under NI 51-102 Describing the transaction.**

Press Release dated October 10, 2018

Press Release dated December 4, 2018

Management Discussion & Analysis for six month period ended September 30, 2018

Interim financial statements for the six month period ended September 30, 2018

Management Discussion & Analysis for nine month period ended December 31, 2018

Interim financial statements for the nine month period ended December 31, 2018

Press Release dated February 1, 2019

Share Purchase Agreement dated February 28, 2019

Press Release dated March 1, 2019

Management Discussion & Analysis year ended March 31, 2019

Audited financial statements for the year ended March 31, 2019

Press Release dated August 26, 2019

Press Release dated August 29, 2019

Management Discussion & Analysis for three month period ended June 30, 2019

Interim financial statements for the three month period ended June 30, 2019

The documents above may be found under the Company's SEDAR profile at www.sedar.com.

This notice is dated September 11, 2019.

SIRE BIOSCIENCE INC.

Sean McGrath, CFO

416.262.0871